Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Glybera
Biotech
Sanofi drops Voyager’s phase 2/3 Parkinson’s gene therapy
The decision gives Voyager the full global rights to VY-AADC but leaves it without a partner as it gears up for a pivotal global phase 2/3 trial.
Nick Paul Taylor
Oct 31, 2017 8:45am
Meyer leaves troubled uniQure for R&D post at Therachon
Aug 29, 2017 9:36am
Chiesi dumps uniQure’s hemophilia B gene therapy
Aug 1, 2017 4:48am